Automated Insulin Delivery Associated with Superior Glycemic Outcomes in Type 1 Diabetes: A Swedish National Registry Analysis
An erratum to this article was published (Diabetes Technol Ther, Aug 2026 ↗)
Authors' conclusion
In a nationwide RWD analysis, AID use was consistently associated with clinically and statistically significant HbA1c reductions in adults with T1D, with the greatest effect for Tandem Control-IQ technology.
Study context
- Population
- Adults (≥18 years) with T1D in the Swedish National Diabetes Register, 2014–2024
- Exposure
- Insulin delivery/glucose monitoring combinations vs MDI with CGM (MDI-CGM)
- Outcome
- HbA1c (averaged per person-year, aggregated by clinic), adjusted
Methodological detailsnationwide, mixed-model regression with random effects for clinics, weighted by clinic sample size
- Nationwide
- Mixed-model regression with random effects for clinics, weighted by clinic sample size
Main finding
As reported in the abstract
Adjusted HbA1c
- Automated insulin delivery (AID)
- β −4.0 mmol/mol (95% CI −4.3 to −3.7); P < 0.001
- Tandem Control-IQ
- β −4.8 mmol/mol (95% CI −5.2 to −4.5); P < 0.001
- Medtronic 780G
- β −3.1 (95% CI −3.5 to −2.7); P < 0.001
- Medtronic 670G
- β −2.9 (95% CI −3.5 to −2.4); P < 0.001
- CSII with CGM (CSII-CGM)
- β −1.7 mmol/mol (95% CI −1.9 to −1.4); P < 0.001
Observational data: associations, not effects.
Original publication
Automated Insulin Delivery Associated with Superior Glycemic Outcomes in Type 1 Diabetes: A Swedish National Registry Analysis. Diabetes Technol Ther. Published 23 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →